TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes - Wikidata - awgldk - TriplyDB

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

http://www.wikidata.org/entity/Q37566878

about

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.The p53 protein plays a central role in the mechanism of action of epigentic drugs that alter the methylation of cytosine residues in DNA.Therapy-related myeloid neoplasms: when genetics and environment collide.A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.Acute myeloid leukemia in the elderly: therapeutic options and choice.Patterns of Care and Survival for Elderly Acute Myeloid Leukemia-Challenges and Opportunities.Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.Treatment of Low-Blast Count AML using Hypomethylating Agents.CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.Detecting truly clonal alterations from multi-region profiling of tumours Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.Targeting apoptosis in acute myeloid leukaemia.Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.Emerging therapeutic modalities for acute myeloid leukemia (AML) in older adults.The interplay between epigenetic changes and the p53 protein in stem cells.Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome - not because we can, but because we should.SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome.Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders.A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia.Erythroleukemia-historical perspectives and recent advances in diagnosis and management.Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.Putting p53 in Context.Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history.Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation.Pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, combined with azacitidine, in patients with AML.Immunological effects of hypomethylating agents.Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.

P2860

Q33869257-44180A76-6EB5-4A99-BAE1-AC948FEC00BE Q37702494-AE5995FC-0C96-49F1-B23F-17E505013D36 Q38611096-4B081AEF-C8AC-4BF3-B2B4-0FA537DD981F Q38651923-ECEEC33C-CCA6-43BD-88E5-E6FC244F372A Q38675781-B55D8BC4-3231-489D-BAAA-0C6862A4CA73 Q38676390-438A8E49-211A-4CA5-AE42-B2221BEB3E1A Q38719539-5FE1D022-A3B3-4821-96BC-DA019F92A51D Q38917137-80EF22BA-C5BA-4BCA-9227-745AB79F9090 Q39092515-8417E626-49EA-4F92-A219-F145414DD593 Q39295844-A79FED87-FBC5-467C-9BF7-4A10DC2A8282 Q39413114-A87E49E6-24BF-46DE-8295-BB78AACB6EDC Q39429687-F4485FBD-19BE-48A1-93E6-874CE3C9935F Q40118769-EE97F7F2-F664-409E-8A07-48E4E1715324 Q40236553-B4E8E4D2-BD67-478C-915B-A969D0DE30A5 Q41790379-AA8AB4FE-1C32-4D38-851E-0B938FC89E05 Q42368321-0C52AE5E-BE1F-48DD-B930-0C8FA49C261D Q44176860-A24059A7-9B00-451A-B1CE-663F723A3FE5 Q44489428-D1BA82B9-FAE4-4A18-9851-B4D2B7197533 Q45923418-644D3023-8C2A-4175-8C3C-9833B992FD11 Q46168137-B39E8C03-7A07-4421-870E-B9E63FAB4072 Q47101729-C9A4F7EA-AE37-4CC4-9518-BCD2D2515BC5 Q47125142-5D2B9D03-2D76-425B-AADE-00549C31F67A Q47134198-738C578C-386B-44D1-89F5-4B0D86EF1B62 Q47140333-C7FC424E-DF8D-4A6C-8768-ACD59330E827 Q47145985-03F85661-C211-4FD4-8896-EA7468023314 Q47146837-387702F0-D99C-49C9-BD7A-AC4E97DC1197 Q47250939-E7CB7B20-D96D-43D1-B802-DC949525EC2B Q47307310-42A18581-085A-4756-BCEC-ABE91122CA3A Q47548041-79D0D58C-E977-478B-ABB3-2D512F8D9657 Q47594672-FDD3B196-EB32-4860-B511-D58A97A7AD97 Q47719432-C90B1F97-26E4-4C6D-893A-428461A941C2 Q47769552-198BF00F-858C-48BC-83DB-7C993A9EC22C Q47833426-5F21FE65-7D10-46E0-9942-FE84A9A3F9E4 Q48123477-EE743333-7C31-460D-A2F7-2E6EEB9A32A6 Q48165068-1EDE8084-D736-4323-A2B0-8E81143A4437 Q48216923-1ADE46AC-A19A-4133-935C-5F2CD34CE314 Q48229616-4C414A19-F6FF-4E51-88B1-56547D695DB1 Q48233351-2FD1C204-5C62-46DF-B978-E72D36E386A1 Q48323548-76E1B291-9693-49EB-89B4-4DDFB44DBB5B Q48533330-156BC830-E6F7-489F-8002-F51456728DFE

P2860

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

http://www.wikidata.org/entity/Q37566878

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

@en

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

@nl

type

label

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

@en

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

@nl

prefLabel

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

@en

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

@nl

P1433

Q37566878-A3615EEC-BC86-453A-911C-ABBEFC543E51

P1476

Q37566878-70A0486B-771A-4A61-B1B9-AC7DA37ADE20

P2093

Q37566878-065880A9-4F1F-40EF-B66A-6024298F8CD8

Q37566878-113F2880-38AD-44ED-A33A-62EC495675E8

Q37566878-11576C0D-23B6-4837-AAB7-566880310CC3

Q37566878-17FB3B64-1F2F-4F34-A047-F8A7C7CFC015

Q37566878-216F07E2-9D4A-4287-99C4-79A33709421D

Q37566878-22E88A11-B390-47B8-AA57-8FB6B854EDD4

Q37566878-23CAAF29-653F-48D6-BA11-AEB8EBE5A4E7

Q37566878-329E0336-EB8E-4B48-A64F-C212CC935B93

Q37566878-37F88E07-78CD-4734-A2D1-368D891DD308

Q37566878-3CCC5540-3493-4EDC-8862-EB252CBB5B0E

P2860

Q37566878-0FE142CF-C35B-4A92-84E7-688731DFD174

Q37566878-16EA3003-61DE-428C-BD3A-317F8471EE2D

Q37566878-19829660-C27C-4F9C-9C88-59AA52BC8D6D

Q37566878-1C59D516-73DD-4F08-AAC0-6B1FF0AC816A

Q37566878-2278C684-5935-45F3-91B0-7DDEEDE16FBA

Q37566878-26BF79E5-052F-4965-81A5-F745A8F2BD64

Q37566878-2F831927-BE8B-40ED-AE92-49BB4FAD0BCB

Q37566878-31DAC05D-E998-4B6B-983B-A61828F45C10

Q37566878-371E6F39-4291-4DA3-941C-A23AFF127CF9

Q37566878-50A34474-F5B5-4EE0-94A0-0E006C10AD82

P304

Q37566878-85D42DB4-83C1-48B3-9196-3F2B460CB542

P31

Q37566878-9367892C-EE76-4A1F-9AF1-0980F781F0FD

P356

Q37566878-EFA11ED4-EF02-4B1A-9ECF-91E9A71DD065

P407

Q37566878-CAB3372E-93AE-4344-B096-4FCFD5BCF8A8

P433

Q37566878-95A50EDA-4635-4FA8-8389-FC3C33E51F5E

P478

Q37566878-9EAED60A-C200-4A01-82BD-0BD23B6D71C3

P50

Q37566878-1E2E151B-2F91-429A-A141-518F433B2889

Q37566878-9A0CA03F-5094-4D55-BBE6-3D725A0C3D5E

P577

Q37566878-34F34620-C645-41E2-959E-9EB5AA4EA552

P698

Q37566878-F55399C8-E531-4707-B897-0F1E1CE7D5C2

P921

Q37566878-70C2445A-CE79-43FA-8BB6-155A2FE59720

P932

Q37566878-681F31FB-8376-460D-BA58-A6FC3CABBABF

P356

P1433

The New England Journal of Medicine

P1476

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

@en

P2093

Allegra A Petti

http://www.w3.org/2001/XMLSchema#string

Amanda F Cashen

http://www.w3.org/2001/XMLSchema#string

Armin Ghobadi

http://www.w3.org/2001/XMLSchema#string

Bevan Tandon

http://www.w3.org/2001/XMLSchema#string

Camille N Abboud

http://www.w3.org/2001/XMLSchema#string

Catrina C Fronick

http://www.w3.org/2001/XMLSchema#string

Christopher A Miller

http://www.w3.org/2001/XMLSchema#string

Daniel C Link

http://www.w3.org/2001/XMLSchema#string

Eric J Duncavage

http://www.w3.org/2001/XMLSchema#string

Geoffrey L Uy

http://www.w3.org/2001/XMLSchema#string

P2860

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.

Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations

TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.

Detectable clonal mosaicism from birth to old age and its relationship to cancer

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence

Age-related clonal hematopoiesis associated with adverse outcomes

Age-related mutations associated with clonal hematopoietic expansion and malignancies

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

P304

2023-2036

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1605949

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Randall W Knoebel

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27959731

http://www.w3.org/2001/XMLSchema#string

P921

P932

5217532

http://www.w3.org/2001/XMLSchema#string